치료에 탁월한 반응을 보이는 암 환자의 조직 샘플에서 분자 프로파일링
탁월한 반응자 파일럿 연구: 탁월한 반응자인 암 환자의 종양에 대한 분자 프로파일링
This pilot research trial studies molecular profiling in tissue samples from patients with cancer who got better with treatment that didn't work for most other patients with the same disease. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to how well patients respond to treatment.
연구 개요
상세 설명
PRIMARY OBJECTIVES:
I. To identify molecular indicators in malignant tissues from patients who were exceptional responders on clinical trials or standard systemic treatments using whole exome and/or targeted deep sequencing, as well as potentially other sequencing and other molecular characterization methods (if adequate tissue exists).
II. To explore associations between the identified molecular indicators and the putative mechanism of action of the treatment received by the patient.
III. To test the feasibility of identifying "exceptional responders", obtaining the relevant tumor and normal tissue and clinical data, and performing whole exome and/or targeted deep sequencing on these samples.
OUTLINE:
Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted next generation sequencing (NGS) assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, messenger ribonucleic acid (RNA) (mRNA)-sequencing, micro (miRNA) sequencing, promoter methylation analysis, and single nucleotide polymorphism (SNP) analysis.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
California
-
Duarte, California, 미국, 91010
- City of Hope Comprehensive Cancer Center
-
Fresno, California, 미국, 93720
- Kaiser Permanente-Fresno
-
Oakland, California, 미국, 94611
- Kaiser Permanente-Oakland
-
Richmond, California, 미국, 94801
- Kaiser Permanente-Richmond
-
San Francisco, California, 미국, 94158
- UCSF Medical Center-Mission Bay
-
Santa Clara, California, 미국, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, 미국, 95403
- Kaiser Permanente-Santa Rosa
-
Stockton, California, 미국, 95210
- Kaiser Permanente-Stockton
-
Walnut Creek, California, 미국, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- UCHealth University of Colorado Hospital
-
Fort Collins, Colorado, 미국, 80524
- Poudre Valley Hospital
-
-
Connecticut
-
Greenwich, Connecticut, 미국, 06830
- Greenwich Hospital
-
-
Delaware
-
Newark, Delaware, 미국, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, 미국, 19713
- Medical Oncology Hematology Consultants PA
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20016
- Sibley Memorial Hospital
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Emory University Hospital/Winship Cancer Institute
-
Columbus, Georgia, 미국, 31904
- John B Amos Cancer Center
-
Valdosta, Georgia, 미국, 31602
- South Georgia Medical Center/Pearlman Cancer Center
-
-
Idaho
-
Boise, Idaho, 미국, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
-
Illinois
-
Chicago, Illinois, 미국, 60631
- Presence Resurrection Medical Center
-
Chicago, Illinois, 미국, 60612
- Rush MD Anderson Cancer Center
-
Decatur, Illinois, 미국, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, 미국, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Evanston, Illinois, 미국, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Peoria, Illinois, 미국, 61615
- Illinois CancerCare-Peoria
-
Springfield, Illinois, 미국, 62702
- Springfield Clinic
-
-
Iowa
-
Cedar Rapids, Iowa, 미국, 52402
- Physicians' Clinic of Iowa PC
-
-
Maine
-
York Village, Maine, 미국, 03909
- York Hospital
-
-
Maryland
-
Bethesda, Maryland, 미국, 20892
- NCI - Center for Cancer Research
-
Bethesda, Maryland, 미국, 20892
- National Cancer Institute Developmental Therapeutics Clinic
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, 미국, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, 미국, 48114
- Trinity Health Medical Center - Brighton
-
Detroit, Michigan, 미국, 48201
- Wayne State University/Karmanos Cancer Institute
-
Grand Rapids, Michigan, 미국, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Marquette, Michigan, 미국, 49855
- UP Health System Marquette
-
Marquette, Michigan, 미국, 49855
- UP Health System Hematology Oncology Marquette
-
Southfield, Michigan, 미국, 48075
- Henry Ford Health Providence Southfield Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, 미국, 63703
- Saint Francis Medical Center
-
Springfield, Missouri, 미국, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, 미국, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, 미국, 63110
- Washington University School of Medicine
-
St Louis, Missouri, 미국, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, 미국, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Great Falls, Montana, 미국, 59405
- Benefis Sletten Cancer Institute
-
-
New Hampshire
-
Portsmouth, New Hampshire, 미국, 03802
- Portsmouth Regional Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Rochester, New York, 미국, 14642
- University of Rochester
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, 미국, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, 미국, 58122
- Sanford Roger Maris Cancer Center
-
-
Ohio
-
Columbus, Ohio, 미국, 43214
- Riverside Methodist Hospital
-
-
Oklahoma
-
Lawton, Oklahoma, 미국, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, 미국, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, 미국, 97227
- Kaiser Permanente Northwest
-
-
Pennsylvania
-
Phoenixville, Pennsylvania, 미국, 19460
- Reading Hospital McGlinn Cancer Institute at Phoenixville
-
West Chester, Pennsylvania, 미국, 19380
- Chester County Hospital
-
West Reading, Pennsylvania, 미국, 19611
- Reading Hospital
-
-
South Carolina
-
Greenville, South Carolina, 미국, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, 미국, 29605
- Prisma Health Cancer Institute - Butternut
-
Seneca, South Carolina, 미국, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, 미국, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Kingsport, Tennessee, 미국, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
-
Texas
-
Houston, Texas, 미국, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Houston, Texas, 미국, 77030
- Ben Taub General Hospital
-
San Antonio, Texas, 미국, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908
- University of Virginia Cancer Center
-
-
West Virginia
-
Martinsburg, West Virginia, 미국, 25401
- WVUH-Berkely Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Summit, Wisconsin, 미국, 53066
- Aurora Medical Center in Summit
-
Waukesha, Wisconsin, 미국, 53188
- UW Cancer Center at ProHealth Care
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients with cancer participating in the Exceptional Cases Initiative
설명
Inclusion Criteria:
-
Documented exceptional response, defined as patients meeting the following criteria:
-
Complete response to a regimen in which complete response is expected in < 10% of similarly treated patients
-
Partial response (PR) > 6 months in a regimen in which PRs > 6 months are expected in < 10% of patients with similar disease treated with same or similar regimen
-
Complete response (CR) or PR of unusual duration, such that the internal review committee considers it to be an exceptional response; examples below:
- PR of duration > 3 x the median expected PR duration (in cases where PR is expected in > 10% of patients with the same disease treated with the same regimen)
- CR or duration > 3 x the median expected CR duration (in cases where CR may be seen in > 10% of patients with same disease treated with same regimen)
- The observed duration of CR (or PR) is longer than expected for 90% of patients with same disease treated with same regimen
-
Note: it is not required that the patient be enrolled on a clinical trial when the exceptional response was observed
-
-
Reports of radiologic scans or other evidence documenting response will be submitted for review; cases where response is not assessable (e.g. adjuvant treatment) will not be eligible because the outcome can not be attributed to a specific treatment
-
Treatment history must be available, for prior treatment and for the drug to which the exceptional response occurred
-
Patient must meet consent criteria; this requires: (i) current exceptional responder (ER) consent by a living participant not lost to follow-up, (ii) prior consent for future research by a participant not known to be deceased, but lost to follow-up, or (iii) if patient is deceased and did not decline to participate in research at the time of tissue removal for any tissue that would be used in this study, then no consent is required
-
Tumor sample available that meets study requirements
-
Required tumor samples MUST exist and be able to be submitted; investigators wishing to submit samples must not have made agreements that would prohibit the free use of data from such samples; the National Cancer Institute (NCI) will provide investigators with a letter for the collaborator amending their existing agreement to allow for the case to be submitted
- Tumor tissue from prior to administration of the drug to which the exceptional response occurred is required; ideally this sample will have been collected just prior to treatment, but other prior tissue will be considered; tissue may be fresh frozen or formalin-fixed paraffin embedded
- Tumor tissue amount must be at least a core biopsy, and meet minimum specimen requirements
-
Encouraged: normal tissue sample: (optional): blood or other specimen source for germline sequencing
-
The tumor samples and clinical data submitted to the Exceptional Responders Database in database in Genotypes and Phenotypes (dbGaP) will need to have appropriate agreements in place to allow for the submission; the Exceptional Responders Database can accept clinical data and samples from cases enrolled on a Cancer Therapy Evaluation Program (CTEP) sponsored clinical trial and cases that were not enrolled on any clinical trial; if the response occurred on a trial that was not CTEP-sponsored, there are existing agreements between the submitting site and the pharmaceutical company; if existing agreements do not allow for the submission of sample and clinical data, the NCI will provide the investigators with a letter that allows the tissue to be used for the exceptional responders study if signed by the appropriate collaborator; the letter modifies the existing agreement to include the CTEP Intellectual Property (IP) Option language that would allow the case to be submitted to the Exceptional Responders Database; if the existing agreement cannot be modified and the letter cannot be signed, the proposed case will not be accepted; Note: as stated above, the patient does not need to have been enrolled on a clinical trial to be eligible for the exceptional responders study
Exclusion Criteria:
- Patient's response did not meet criteria for an exceptional response
- Patient's treatment regimen is expected to lead to CR or durable PR in > 10% of patients
- Patient's duration of response is not > 3 x expected median length of response
- Response not evaluable or not able to be attributed to systemic treatment (e.g. adjuvant treatment)
- Patient refused consent for use of tissue for research activities included in the exceptional responders study
- Tumor sample from prior to the exceptional response is not available, or does not meet quality metrics
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: CASE_CONTROL
- 시간 관점: RETROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Ancillary-Correlative (molecular profiling)
Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted NGS assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, mRNA-sequencing, miRNA sequencing, promoter methylation analysis, and SNP analysis. |
Undergo sequencing and SNP analysis |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Molecular features in tissue samples from patients who were exceptional responders
기간: Baseline
|
The molecular features of the tumors in the patients will be discernible as distinct to the tumor by comparison to (i) samples from normal tissue in the same patient and (ii) databases of similar data for normal and other tumor types. |
Baseline
|
|
Putative mechanisms of action of the treatments that the patients received when they experienced their exceptional responses
기간: Baseline
|
The associations between identified molecular features and the putative mechanisms of action of the treatments that the patients received when they experienced their exceptional responses will be explored. Statistical analyses will be primarily descriptive. |
Baseline
|
|
Number of cases identified as potential exceptional responders
기간: Baseline
|
Statistical analyses will be primarily descriptive. |
Baseline
|
|
Percentage of identified potential cases confirmed to be exceptional responders
기간: Baseline
|
Statistical analyses will be primarily descriptive. |
Baseline
|
|
Percentage of confirmed exceptional responders for which adequate tissue with appropriate informed consent is acquired
기간: Baseline
|
Statistical analyses will be primarily descriptive. |
Baseline
|
|
Percentage of acquired cases with tissue for which at least the minimum molecular characterization is successfully obtained
기간: Baseline
|
Statistical analyses will be primarily descriptive. |
Baseline
|
|
Percentage of molecularly characterized cases for which a Molecular Characterization report identified (without reference to the drug received by the patient) at least one feature judged to have potential therapeutic relevance
기간: Baseline
|
Promising discoveries will be summarized for the group of cases for which the minimum molecular characterization was successfully obtained. For each such case, molecular data will be reviewed by an expert panel ("Panel") to identify interesting features. All estimated proportions will be accompanied by exact 95% confidence intervals. |
Baseline
|
|
Percentage of cases with >= 1 feature on Molecular Characterization report that was judged to have potential therapeutic relevance to the specific class of drug the patient actually received when the exceptional response was experienced
기간: Baseline
|
Promising discoveries will be summarized for the group of cases for which the minimum molecular characterization was successfully obtained. For each such case, molecular data will be reviewed by the Panel to identify interesting features. All estimated proportions will be accompanied by exact 95% confidence intervals. |
Baseline
|
|
Percentage of cases with >= 1 feature that correlates with the mechanism of action of the specific grant to which the exceptional response occurred that was found after further analyzing the molecular profile data for relevant molecular abnormalities
기간: Baseline
|
Promising discoveries will be summarized for the group of cases for which the minimum molecular characterization was successfully obtained. For each such case, molecular data will be reviewed by the Panel to identify interesting features. All estimated proportions will be accompanied by exact 95% confidence intervals. |
Baseline
|
공동 작업자 및 조사자
수사관
- 수석 연구원: S. P Ivy, National Cancer Institute (NCI)
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NCI-2014-01585
- UM1CA186704 (미국 NIH 보조금/계약)
- 9671 (기타 식별자: CTEP)
- NCI-2014-01585 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- 9671 (기타 식별자: National Cancer Institute)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .